The emergence of drug resistant clones of tumor cells remains one of the major limitations of cancer chemotherapy. Relatively little is known of the genetic mechanisms which may underly the development of drug resistance. Model systems in which tissue culture cells have been selected for a drug resistance phenotype are very useful in the study of this phenomenon. In many instances, selection in vitro with antimetabolites has led to the emergence of drug resistant mutants in which resistance is the consequence of amplification of a specific drug resistance gene. A human colon cancer cell line, WIDR/s, and its mitoxantrone resistant sub-clone WIDR/r are described. Preliminary studies are presented which demonstrate that WIDR/r exhibits cytogenetic evidence of gene amplification, a chromosome 7 HSR. The presence of an amplified domain is verified on renaturation gel analysis, and Southern blotting with a P-glycoprotein probe demonstrates that the amplified domain does not include the P- glycoprotein. A series of experiments is proposed to characterize the amplified gene which may be responsible for resistance to mitoxantrone. We will obtain and characterize cDNA clones of the target gene and use DNA transfection to transfer the resistant phenotype to sensitive cells. These studies will lay the ground work for a mechanistic analysis of mitoxantrone resistance.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
1P01CA041183-01A1
Application #
3938920
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
1987
Total Cost
Indirect Cost
Name
University of Arizona
Department
Type
DUNS #
City
Tucson
State
AZ
Country
United States
Zip Code
85722
Nelson, M A; Radmacher, M D; Simon, R et al. (2000) Chromosome abnormalities in malignant melanoma: clinical significance of nonrandom chromosome abnormalities in 206 cases. Cancer Genet Cytogenet 122:101-9
Simon, R; Desper, R; Papadimitriou, C H et al. (2000) Chromosome abnormalities in ovarian adenocarcinoma: III. Using breakpoint data to infer and test mathematical models for oncogenesis. Genes Chromosomes Cancer 28:106-20
Taetle, R; Aickin, M; Yang, J M et al. (1999) Chromosome abnormalities in ovarian adenocarcinoma: I. Nonrandom chromosome abnormalities from 244 cases. Genes Chromosomes Cancer 25:290-300
Taetle, R; Aickin, M; Panda, L et al. (1999) Chromosome abnormalities in ovarian adenocarcinoma: II. Prognostic impact of nonrandom chromosome abnormalities in 244 cases. Genes Chromosomes Cancer 25:46-52
Meloni-Ehrig, A M; Chen, Z; Guan, X Y et al. (1999) Identification of a ring chromosome in a myxoid malignant fibrous histiocytoma with chromosome microdissection and fluorescence in situ hybridization. Cancer Genet Cytogenet 109:81-5
Ozisik, Y Y; Meloni, A M; Spanier, S S et al. (1998) Deletion 1p in a low-grade chondrosarcoma in a patient with Ollier disease. Cancer Genet Cytogenet 105:128-33
Kline, R M; Oseas, R S; Jolley, S G et al. (1997) Leptomeningeal metastasis from a paraspinal rhabdomyosarcoma with a der(13)t(1;13)(q23;q32) in a 14-month-old boy. Cancer Genet Cytogenet 98:97-101
Kingsley, K L; Peier, A M; Meloni-Ehrig, A M et al. (1997) Cytogenetic findings in a bladder chondrosarcoma. Cancer Genet Cytogenet 96:183-4
Paine-Murrieta, G D; Taylor, C W; Curtis, R A et al. (1997) Human tumor models in the severe combined immune deficient (scid) mouse. Cancer Chemother Pharmacol 40:209-14
Thompson, F H; Taetle, R; Trent, J M et al. (1997) Band 1p36 abnormalities and t(1;17) in ovarian carcinoma. Cancer Genet Cytogenet 96:106-10

Showing the most recent 10 out of 133 publications